Feature|Podcasts|November 17, 2025

Raising Biomarker Awareness

Author(s)Mike Hollan

Dr. Jaspal Singh explains some of the barriers that prevent cancer patients from getting biomarker testing early in their treatment journey.

Dr. Jaspal Singh, MD, medical director for critical care practice and education at Atrium Health discusses a white paper on optimizing molecular testing for lung and bladder cancers. The paper highlighted gaps in molecular testing, emphasizing the need for better specimen management and education. Lung cancer, which kills more people in the U.S. than any other cancer, was particularly noted for its aggressive nature and late diagnosis. Barriers include pragmatic issues, insurance coverage confusion, and outdated clinical practices. The team proposed reflex testing, combining tissue and blood tests upfront, to improve treatment precision and outcomes. Education for both clinicians and patients is crucial to bridge these gaps.

  • Dr Singh explains the gap between the availability of testing and its execution, and the implications of the science.
  • Patients are often scared and want to start treatment immediately, which can lead to a lack of precise therapy.
  • Non-small cell lung cancer has a higher percentage of people getting tested compared to bladder and prostate cancer.
  • The field of oncology is evolving rapidly, and many doctors may not keep up with the latest advancements.

Related to this article

Pharmaceutical Executive Daily
FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.
Pharmaceutical Executive Daily
FDA approves Merck KGaA’s Pimjetmi for tenosynovial giant cell tumor, Parexel’s Stacy Hurt on when patient input should enter the clinical research process, and Ignite Proteomics’ Dr. Brian Corgiat on adjusting for tumor mutations in treatment decisions.
Pharmaceutical Executive daily
argenx acquires Unnatural Products for up to $1.15 billion to expand its immunology capabilities, GiftHealth’s Chip Parkinson on how single-partner platforms can transform the prescription journey, and Partha Anbil on why competing on net value matters more than cutting list prices as US drug pricing resets.
Pharmaceutical Executive Daily
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.